Comparative Pharmacology
Head-to-head clinical analysis: LEXAPRO versus PEXEVA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEXAPRO versus PEXEVA.
LEXAPRO vs PEXEVA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin reuptake at the presynaptic neuron, potentiating serotonergic activity.
Paroxetine is a selective serotonin reuptake inhibitor (SSRI); it potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane.
10 mg orally once daily; may increase to 20 mg once daily after at least 1 week.
Initial 10 mg orally once daily, increased gradually based on response and tolerability; maximum 50 mg once daily (paroxetine hydrochloride equivalent).
None Documented
None Documented
27-32 hours (mean ~30 h); steady state reached in ~1 week; linear kinetics at therapeutic doses.
60-120 hours (chronic dosing); steady-state achieved in 4-5 weeks
Primarily renal (approx. 80% as metabolites, 8% as unchanged drug); biliary/fecal elimination accounts for ~15%.
Primarily renal (70% as metabolites, 2% unchanged); fecal (27%)
Category C
Category C
SSRI Antidepressant
SSRI Antidepressant